The expression of BMP, integrin, ZEB2 in ovarian high-grade serous carcinoma in relation with lymph node metastasis

References

• Arikan, S. K., B. Kasap, H. Yetimalar, A. Yildiz, D. K. Sakarya, and S. Tatar. 2014. “Impact of Prognostic Factors on Survival Rates in Patients with Ovarian Carcinoma.” Asian Pacific Journal of Cancer Prevention : APJCP 15 (15): 6087–6094. doi:10.7314/apjcp.2014.15.15.6087.
   PubMedGoogle Scholar
• Berrier, A. L., and K. M. Yamada. 2007. “Cell-matrix Adhesion.” Journal of Cellular Physiology 213 (3): 565–573. doi:10.1002/jcp.21237.
   PubMed Web of Science ®Google Scholar
• Buijs, J. T., N. V. Henriquez, P. G. van Overveld, G. van der Horst, P. ten Dijke, and G. van der Pluijm. 2007. “TGF-Beta and BMP7 Interactions in Tumour Progression and Bone Metastasis.” Clinical & Experimental Metastasis 24 (8): 609–617. doi:10.1007/s10585-007-9118-2.
   PubMed Web of Science ®Google Scholar
• Chen, C. H., M. K. Shyu, S. W. Wang, C. H. Chou, M. J. Huang, T. C. Lin, S. T. Chen, H. H. Lin, and M. C. Huang. 2016. “MUC20 Promotes Aggressive Phenotypes of Epithelial Ovarian Cancer Cells via Activation of the Integrin Beta1 Pathway.” Gynecologic Oncology 140 (1): 131–137. doi:10.1016/j.ygyno.2015.11.025.
   PubMed Web of Science ®Google Scholar
• Conidi, Andrea, Veronique van den Berghe, Kris Leslie, Agata Stryjewska, Hua Xue, Ye-Guang Chen, Eve Seuntjens, and Danny Huylebroeck. 2013. “Four Amino Acids within a Tandem QxVx Repeat in a Predicted Extended α-Helix of the Smad-binding Domain of Sip1 Are Necessary for Binding to Activated Smad Proteins.” PloS One 8 (10): e76733. doi:10.1371/journal.pone.0076733.
   PubMed Web of Science ®Google Scholar
• Ganguly, K. K., S. Pal, S. Moulik, and A. Chatterjee. 2013. “Integrins and Metastasis.” Cell Adhesion & Migration 7 (3): 251–261. doi:10.4161/cam.23840.
   PubMed Web of Science ®Google Scholar
• Ganguly, K. K., T. Sen, S. Pal, J. Biswas, and A. Chatterjee. 2012. “Studies on Focal Adhesion Kinase in Human Breast Cancer Cell MDA-MB-231.” Advances in Biological Chemistry 02 (01): 29–42. doi:10.4236/abc.2012.21004.
   Google Scholar
• Gertig, D., and D. Hunter. 2002. “Ovarian Cancer.” In Textbook of Cancer Epidemiology, edited by H Adami, D. Hunter and D. Trichopoulos, 378–399. Oxford: Oxford University Press.
   Google Scholar
• Guan, H., J. Li, R. Sun, W. Liu, M. Feng, H. Ma, and C. Li. 2019. “Expression of BMP7 in Ovarian Cancer and Biological Effect of BMP7 Knockdown on Ovarian Cancer Cells.” OncoTargets and Therapy 12: 7897–7909. doi:10.2147/OTT.S217975.
   PubMed Web of Science ®Google Scholar
• Guo, X., and X. F. Wang. 2009. “Signaling Cross-talk between TGF-beta/BMP and Other Pathways.” Cell Research 19 (1): 71–88. doi:10.1038/cr.2008.302.
   PubMed Web of Science ®Google Scholar
• Hibbs, K., K. M. Skubitz, S. E. Pambuccian, R. C. Casey, K. M. Burleson, T. R. Oegema, Jr., J. J. Thiele, S. M. Grindle, R. L. Bliss, and A. P. Skubitz. 2004. “Differential Gene Expression in Ovarian Carcinoma: Identification of Potential Biomarkers.” The American Journal of Pathology 165 (2): 397–414.
   PubMed Web of Science ®Google Scholar
• Ho, C. M., D. T. Shih, C. C. Hsiao, S. H. Huang, S. F. Chang, and W. F. Cheng. 2015. “Gene Methylation of Human Ovarian Carcinoma Stromal Progenitor Cells Promotes Tumorigenesis.” Journal of Translational Medicine 13 (1): 367. doi:10.1186/s12967-015-0722-7.
   PubMedGoogle Scholar
• Hover, L. D., C. D. Young, N. E. Bhola, A. J. Wilson, D. Khabele, C. C. Hong, H. L. Moses, and P. Owens. 2015. “Small Molecule İnhibitor of the Bone Morphogenetic Protein Pathway DMH1 Reduces Ovarian Cancer Cell Growth.” Cancer Letters 368 (1): 79–87. doi:10.1016/j.canlet.2015.07.032.
   PubMed Web of Science ®Google Scholar
• Huang, Peide, Anan Chen, Weiyi He, Zhen Li, Guanglin Zhang, Zhong Liu, Ge Liu, et al. 2017. “BMP-2 İnduces EMT and Breast Cancer Stemness through Rb and CD44.” Cell Death Discovery 3: 17039. doi:10.1038/cddiscovery.2017.39.
   PubMed Web of Science ®Google Scholar
• Kleppe, M., T. Wang, T. Van Gorp, B. F. Slangen, A. J. Kruse, and R. F. Kruitwagen. 2011. “Lymph Node Metastasis in Stages I and II Ovarian Cancer.” Gynecologic Oncology 123 (3): 610–614.
   PubMed Web of Science ®Google Scholar
• Le Page, C., V. Ouellet, J. Madore, F. Ren, T. J. Hudson, P. N. Tonin, D. M. Provencher, and A. M. Mes-Masson. 2006. “Gene Expression Profiling of Primary Cultures of Ovarian Epithelial Cells Identifies Novel Molecular Classifiers of Ovarian Cancer.” British Journal of Cancer 94 (3): 436–445. doi:10.1038/sj.bjc.6602933.
   PubMed Web of Science ®Google Scholar
• Le Page, C., M. L. Puiffe, L. Meunier, M. Zietarska, M. de Ladurantaye, P. N. Tonin, D. Provencher, and A. M. Mes-Masson. 2009. “BMP-2 Signaling in Ovarian Cancer and Its Association with Poor Prognosis.” Journal of Ovarian Research 2: 4. doi:10.1186/1757-2215-2-4.
   PubMed Web of Science ®Google Scholar
• Ma, Y., L. Ma, Q. Guo, and S. Zhang. 2010. “Expression of Bone Morphogenetic Protein-2 and Its Receptors in Epithelial Ovarian Cancer and Their Influence on the Prognosis of Ovarian Cancer Patients.” Journal of Experimental & Clinical Cancer Research: CR 29: 85. doi:10.1186/1756-9966-29-85.
   PubMed Web of Science ®Google Scholar
• Mandal, C. C., M. M. Rahman, and A. Nag. 2015. “An Update of Bone Morphogenetic Proteins as Biomarker and Therapy for Cancer.” Journal of Carcinogenesis & Mutagenesis 6: e114.
   Google Scholar
• Mitra, A. K., K. Sawada, P. Tiwari, K. Mui, K. Gwin, and E. Lengyel. 2011. “Ligand-independent Activation of c-Met by Fibronectin and Alpha(5)beta(1)-integrin Regulates Ovarian Cancer Invasion and Metastasis.” Oncogene 30 (13): 1566–1576. doi:10.1038/onc.2010.532.
   PubMed Web of Science ®Google Scholar
• Moll, F., C. Millet, D. Noel, B. Orsetti, A. Bardin, D. Katsaros, C. Jorgensen, et al. 2006. “Chordin Is Underexpressed in Ovarian Tumors and Reduces Tumor Cell Motility.” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 20 (2): 240–250. doi:10.1096/fj.05-4126com.
   PubMed Web of Science ®Google Scholar
• Naber, Hildegonda P. H., Eliza Wiercinska, Evangelia Pardali, Theo van Laar, Ella Nirmala, Anders Sundqvist, Hans van Dam, et al. 2012. “BMP-7 İnhibits TGF-β-induced İnvasion of Breast Cancer Cells through Inhibition of Integrin β3 Expression.” Cellular Oncology 35 (1): 19–28. doi:10.1007/s13402-011-0058-0.
   Web of Science ®Google Scholar
• Niu, H., W. Zhou, Y. Xu, Z. Yin, W. Shen, Z. Ye, Y. Liu, et al. 2017. “Silencing PPA1 İnhibits Human Epithelial Ovarian Cancer Metastasis by Suppressing the Wnt/beta-catenin Signaling Pathway.” Oncotarget 8 (44): 76266–76278. doi:10.18632/oncotarget.19346.
   PubMedGoogle Scholar
• Pirker, Robert, Jose R. Pereira, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Keunchil Park, Filippo de Marinis, et al. 2012. “EGFR Expression as a Predictor of Survival for First-line Chemotherapy plus Cetuximab in Patients with Advanced Non-small-cell Lung Cancer: Analysis of Data from the Phase 3 FLEX Study.” The Lancet Oncology 13 (1): 33–42. doi:10.1016/S1470-2045(11)70318-7.
   PubMed Web of Science ®Google Scholar
• Pon, Y. L., H. Y. Zhou, A. N. Cheung, H. Y. Ngan, and A. S. Wong. 2008. “p70 S6 Kinase Promotes Epithelial to Mesenchymal Transition through Snail Induction in Ovarian Cancer Cells.” Cancer Research 68 (16): 6524–6532. doi:10.1158/0008-5472.CAN-07-6302.
   PubMed Web of Science ®Google Scholar
• Prat, J. 2015. “Ovarian, Fallopian Tube and Peritoneal Cancer Staging: Rationale and Explanation of New FIGO Staging 2013.” Best Practice & Research. Clinical Obstetrics & Gynaecology 29 (6): 858–869. doi:10.1016/j.bpobgyn.2015.03.006.
   PubMed Web of Science ®Google Scholar
• Prislei, S., E. Martinelli, G. F. Zannoni, M. Petrillo, F. Filippetti, M. Mariani, S. Mozzetti, G. Raspaglio, G. Scambia, and C. Ferlini. 2015. “Role and Prognostic Significance of the Epithelial-mesenchymal Transition Factor ZEB2 in Ovarian Cancer.” Oncotarget 6 (22): 18966–18979. doi:10.18632/oncotarget.3943.
   PubMedGoogle Scholar
• Rahman, M. S., N. Akhtar, H. M. Jamil, R. S. Banik, and S. M. Asaduzzaman. 2015. “TGF-Beta/BMP Signaling and Other Molecular Events: Regulation of Osteoblastogenesis and Bone Formation.” Bone Research 3: 15005. doi:10.1038/boneres.2015.5.
   PubMed Web of Science ®Google Scholar
• Sakai, H., M. Furihata, C. Matsuda, M. Takahashi, H. Miyazaki, T. Konakahara, T. Imamura, and T. Okada. 2012. “Augmented Autocrine Bone Morphogenic Protein (BMP) 7 Signaling İncreases the Metastatic Potential of Mouse Breast Cancer Cells.” Clinical & Experimental Metastasis 29 (4): 327–338. doi:10.1007/s10585-012-9453-9.
   PubMed Web of Science ®Google Scholar
• Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. “Cancer Statistics, 2014.” CA: A Cancer Journal for Clinicians 64 (1): 9–29. doi:10.3322/caac.21208.
   PubMed Web of Science ®Google Scholar
• Sun, Z. L., Y. J. Tang, W. G. Wu, J. Xing, Y. F. He, D. M. Xin, Y. L. Yu, Y. Yang, and P. Han. 2013. “AZD1480 Can İnhibit the Biological Behavior of Ovarian Cancer SKOV3 Cells In Vitro.” Asian Pacific Journal of cancer prevention: APJCP 14 (8): 4823–4827. doi:10.7314/apjcp.2013.14.8.4823.
   PubMedGoogle Scholar
• Sunde, J. S., H. Donninger, K. Wu, M. E. Johnson, R. G. Pestell, G. S. Rose, S. C. Mok, J. Brady, T. Bonome, and M. J. Birrer. 2006. “Expression Profiling İdentifies Altered Expression of Genes that Contribute to the Inhibition of Transforming Growth Factor-beta Signaling in Ovarian Cancer.” Cancer Research 66 (17): 8404–8412. doi:10.1158/0008-5472.CAN-06-0683.
   PubMed Web of Science ®Google Scholar
• Urist, M. R. 1965. “Bone: Formation by Autoinduction.” Science 150 (3698): 893–899. doi:10.1126/science.150.3698.893.
   PubMed Web of Science ®Google Scholar
• Vaughan, S., J. I. Coward, R. C. Bast, Jr., A. Berchuck, J. S. Berek, J. D. Brenton, G. Coukos, et al. 2011. “Rethinking Ovarian Cancer: Recommendations for Improving Outcomes.” Nature Reviews. Cancer 11 (10): 719–725. doi:10.1038/nrc3144.
   PubMed Web of Science ®Google Scholar
• Vergara, D., B. Merlot, J. P. Lucot, P. Collinet, D. Vinatier, I. Fournier, and M. Salzet. 2010. “Epithelial-mesenchymal Transition in Ovarian Cancer.” Cancer Letters 291 (1): 59–66. doi:10.1016/j.canlet.2009.09.017.
   PubMed Web of Science ®Google Scholar
• Verschueren, K., J. E. Remacle, C. Collart, H. Kraft, B. S. Baker, P. Tylzanowski, L. Nelles, et al. 1999. “SIP1, a Novel Zinc Finger/Homeodomain Repressor, Interacts with Smad Proteins and Binds to 5′-CACCT Sequences in Candidate Target Genes.” The Journal of Biological Chemistry 274 (29): 20489–20498.
   PubMed Web of Science ®Google Scholar
• Wang, R. N., J. Green, Z. Wang, Y. Deng, M. Qiao, M. Peabody, Q. Zhang, et al. 2014. “Bone Morphogenetic Protein (BMP) Signaling in Development and Human Diseases.” Genes & Diseases 1 (1): 87–105. doi:10.1016/j.gendis.2014.07.005.
   PubMedGoogle Scholar
• Ying, Xuexiang., Yunpo. Sun, and Pingqing. He. 2015. “Bone Morphogenetic Protein-7 İnhibits EMT-associated Genes in Breast Cancer.” Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 37 (4): 1271–1278. doi:10.1159/000430249.
   PubMedGoogle Scholar
• Ying, X., Y. Sun, and P. He. 2017. “MicroRNA-137 İnhibits BMP7 to Enhance the Epithelial-mesenchymal Transition of Breast Cancer Cells.” Oncotarget 8 (11): 18348–18358. doi:10.18632/oncotarget.15442.
   PubMedGoogle Scholar
• Zabkiewicz, C., J. Resaul, R. Hargest, W. G. Jiang, and L. Ye. 2017. “Bone Morphogenetic Proteins, Breast Cancer, and Bone Metastases: Striking the Right Balance.” Endocrine-related Cancer 24 (10): R349–R366. doi:10.1530/ERC-17-0139.
   PubMed Web of Science ®Google Scholar
• Zhang, L., and W. Zou. 2015. “Inhibition of Integrin Beta1 Decreases the Malignancy of Ovarian Cancer Cells and Potentiates Anticancer Therapy via the FAK/STAT1 Signaling Pathway.” Molecular Medicine Reports 12 (6): 7869–7876. doi:10.3892/mmr.2015.4443.
   PubMed Web of Science ®Google Scholar